Hemorrhagic hereditary telangiectasia (HHT) type 2 patients have increased activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway in telangiectasia. The main objective is to evaluate the activation of the PI3K pathway in cutaneous telangiectasia of HHT1 patients. A cutaneous biopsy of a digital hand telangiectasia was performed in seven HHT1 and eight HHT2 patients and compared with six controls. The study was approved by the Clinical Research Ethics Committee of our center. A histopathological pattern with more dilated and superficial vessels that pushed up the epidermis was identified in HHT patients regardless of the type of mutation and was associated with older age, as opposed to the common telangiectasia pattern. The mean proliferation index (Ki-67) was statistically higher in endothelial cells (EC) from HHT1 than in controls. The percentage of positive EC for pNDRG1, pAKT, and pS6 in HHT1 patients versus controls resulted in higher values, statistically significant for pNDRG1 and pS6. In conclusion, we detected an increase in EC proliferation linked to overactivation of the PI3K pathway in cutaneous telangiectasia biopsies from HHT1 patients. Our results suggest that PI3K inhibitors could be used as novel therapeutic agents for HHT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770684PMC
http://dx.doi.org/10.3390/cells8090971DOI Listing

Publication Analysis

Top Keywords

hht1 patients
12
phosphatidylinositol 3-kinase
8
hemorrhagic hereditary
8
hereditary telangiectasia
8
pi3k pathway
8
pathway cutaneous
8
cutaneous telangiectasia
8
patients
7
telangiectasia
7
pi3k
5

Similar Publications

Article Synopsis
  • Prime editing (PE) is a new genome-editing method that offers flexible editing capabilities, yet its use in human induced pluripotent stem cells (hiPSCs) has not been thoroughly explored.
  • The study focused on using PE to create isogenic hiPSC lines to better model hereditary hemorrhagic telangiectasia (HHT1), a genetic disorder, aiming for more accurate representations of human genetics compared to previous animal models.
  • Results showed that PE could successfully introduce specific mutations in hiPSCs without affecting their pluripotency or genetic integrity, enhancing the understanding of disease mechanisms and potential therapies.
View Article and Find Full Text PDF

Endoglin () mutation causes type 1 hereditary hemorrhagic telangiectasia (HHT1). HHT1 patients have arteriovenous malformations (AVMs) in multiple organs, including the brain. In mice, deletion induced by R26RCreER or SM22αCre leads to AVM development in the brain and other organs.

View Article and Find Full Text PDF

Molecular mechanisms and clinical manifestations of hereditary hemorrhagic telangiectasia.

Thromb Res

September 2024

Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Transfusion Department, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:

Introduction: Hereditary Hemorrhagic Telangiectasia (HHT) is charactered by telangiectasia and arteriovenous malformations (AVMs). Recurrent visceral and mucocutaneous bleeding is frequently reported among HHT patients, while data on the prevalence of thrombosis remains limited. This study aims to describe the clinical manifestations and molecular biological characteristics of HHT patients.

View Article and Find Full Text PDF

Hereditary hemorrhagic telangiectasia (HHT), also called Rendu-Osler syndrome, is a group of rare genetic diseases characterized by autosomal dominance, multisystemic vascular dysplasia, and age-related penetrance. This includes arteriovenous malformations (AVMs) in the skin, brain, lung, liver, and mucous membranes. The correlations between the phenotype and genotype for HHT are not clear.

View Article and Find Full Text PDF

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder affecting 1 in 5000-8000 individuals. Hereditary hemorrhagic telangiectasia type 1 (HHT1) is the most common HHT and manifests as diverse vascular malformations ranging from mild symptoms such as epistaxis and mucosal and cutaneous telangiectases to severe arteriovenous malformations (AVMs) in the lungs, brain or liver. HHT1 is caused by heterozygous mutations in the ENG gene, which encodes endoglin, the TGFβ homodimeric co-receptor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!